MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis.
COVID-19
Disease-modifying therapies
Multiple sclerosis
SARS-CoV-2
Vaccines
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
06
08
2021
revised:
20
08
2021
accepted:
23
08
2021
pubmed:
4
9
2021
medline:
17
12
2021
entrez:
3
9
2021
Statut:
ppublish
Résumé
Patients with multiple sclerosis (MS) should be vaccinated against COVID-19. All COVID-19 vaccines are effective and do not appear to carry any additional risk for patients with MS. Patients with MS should get a COVID-19 vaccine as soon as it becomes available. The risks of COVID-19 disease outweigh any potential risks from the vaccine. Even if vaccinated, patients with MS should continue to practice standard and recommended precautions against COVID-19, such as wearing a face mask, social distancing and washing hands. There is no evidence that patients with MS are at higher risk of complications from the mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines, compared to the general population. COVID-19 Vaccines are safe to use in patients with MS treated with disease-modifying therapies (DMTs). The effectiveness of vaccination may be affected by few of the DMTs but yet some protection is still provided. For certain DMTs we may consider coordinating the timing of the vaccine with the timing of the DMT dose to increase vaccine efficacy.
Identifiants
pubmed: 34479111
pii: S2211-0348(21)00492-2
doi: 10.1016/j.msard.2021.103225
pmc: PMC8386106
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103225Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Cancer Gene Ther. 2021 Feb;28(1-2):5-17
pubmed: 32457487
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Mult Scler Relat Disord. 2020 Oct;45:102420
pubmed: 32736217
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S33-40
pubmed: 20061006
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Adv Ther. 2021 Jul;38(7):3550-3588
pubmed: 34075554
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Neurology. 2013 Sep 3;81(10):872-6
pubmed: 23925762
Mult Scler Relat Disord. 2020 Oct;45:102439
pubmed: 32769063
Neurology. 2015 Mar 3;84(9):872-9
pubmed: 25636714
J Clin Immunol. 2013 Feb;33(2):388-96
pubmed: 23064976
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
Mult Scler Relat Disord. 2020 Jun;41:101982
pubmed: 32070858
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Mult Scler. 2021 Mar;27(3):347-359
pubmed: 32940128
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
Clin Exp Immunol. 2017 May;188(2):183-194
pubmed: 28249350
J Immunol. 2009 Feb 15;182(4):1868-76
pubmed: 19201839
J Med Virol. 2021 Jul;93(7):4612-4615
pubmed: 33788281
Mult Scler Relat Disord. 2019 Jun;31:173-188
pubmed: 31159998
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174
pubmed: 30094293
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Cell. 2020 Aug 6;182(3):713-721.e9
pubmed: 32778225
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
J Med Virol. 2021 Jul;93(7):4083-4084
pubmed: 33666244
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088